FDA’s Autologous Cell Therapy Stance Needs Clarification, CTI Says
Executive Summary
FDA needs to address the "unique aspects" of property rights involved in the medical use of autologous cell therapy, Cancer Therapeutics, Inc. told the agency in an exchange of letters regarding the regulatory status of CTI's research programs
You may also be interested in...
Cancer Therapeutics Gets CBER Warning Letter For Website IND Descriptions
Cancer Therapeutics will keep descriptions of its investigational products on its website despite an FDA warning letter requesting their removal
Big Pharma Likes Big Trials, Biotech CEO Says; Tufts Defends R&D Estimate
Large pharmaceutical companies are comfortable with high R&D costs because they create a barrier to entry in the industry, Cancer Therapeutics, Inc. CEO Robert Oldham, MD, maintained during a Capitol Hill briefing sponsored by the Manhattan Institute June 3
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011